Jazz Pharmaceuticals plc — Director's Dealing 2022

Oct 6, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2022-10-03

Reporting Person: COZADD BRUCE C (Director, Chairman & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-10-03	Ordinary Shares	M	62905	$59.13	Acquired	419213	Direct
2022-10-03	Ordinary Shares	S	13791	$134.0227	Disposed	405422	Direct
2022-10-03	Ordinary Shares	S	23646	$135.1766	Disposed	381776	Direct
2022-10-03	Ordinary Shares	S	7748	$135.8045	Disposed	374028	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-10-03	Non-Qualified Stock Option (right to buy)	$59.13	M	62905	Disposed	2023-03-04	Ordinary Shares (62905)	Direct

Footnotes

F1: Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options.

F2: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $133.56 to $134.54. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F3: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $134.57 to $135.56. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F4: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $135.57 to $136.30. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F5: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F6: This non-qualified stock option is part of an option granted on March 5, 2013. The ordinary shares subject to this option vested over 4 years from the grant date with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter and were fully vested as of March 5, 2017.